Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  News  >  Economy & Forex

News : Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

Factbox: Pfizer-BioNTech vaccine days away from UK roll-out

12/02/2020 | 05:45am EST

(Reuters) - Britain on Wednesday became the first country in the world to approve the Pfizer-BioNTech COVID-19 vaccine for use and said that it will be rolled out from early next week.

Drugmaker Pfizer said last month final results from the late-stage trial of its COVID-19 vaccine showed it was 95% effective.

Pfizer said efficacy of the vaccine was consistent across age and ethnic groups, and there were no major side effects, a sign that the immunization could be employed broadly around the world.

Dozens of drugmakers and research groups have been racing to develop vaccines against COVID-19, which has killed more than 1.3 million people, shuttered businesses and left millions out of work around the globe.

Below are the main details of the vaccine and progress on supply deals and potential approvals:


- The vaccine candidate, called BNT162b2, is based on messenger RNA (mRNA) technology, which uses a chemical messenger to instruct cells to make proteins that mimic the outer surface of the new coronavirus, thereby creating immunity.

- mRNA relies on synthetic genes that can be generated and manufactured in weeks, and produced at scale more rapidly than conventional vaccines.

- The new technology has not been approved for any vaccines so far; Pfizer and BioNTech have already collaborated to develop influenza vaccines based on mRNA.


- Based on the supply deal with the United States, the price tag amounts to $39 for what is likely to be a two-dose course of treatment.

- Pfizer has said it will not charge other developed countries a lower price for the vaccine than what the United States will pay.


- BioNTech Chief Executive Officer Ugur Sahin said he was optimistic the immunization effect of the vaccine would last for a year. Scientists do not know how long the effect will last.


- The European Medicines Agency said on Tuesday that if its experts have received enough data from Pfizer about the candidate vaccine against the coronavirus, the agency would complete its reviews by Dec. 29.

- Canada could approve Pfizer's vaccine "around December", a senior official at Canada's drug regulator said on Thursday.

- U.S. FDA granted the vaccine a 'fast track' status in mid-July.

- The European Medicines Agency said in November Pfizer and BioNTech had submitted data from large-scale trial of their potential COVID-19 vaccine for the agency's rolling review, but had not yet applied for approval.

- Pfizer signed a deal worth up to $750 million with BioNTech in March to co-develop the potential vaccine, and it ran clinical trials in April.

- Testing of the vaccine began in the United States in May after trials started in Germany the previous month.


- Trials are continuing globally in 154 locations, including in Germany, Japan, Brazil and in several locations within the United States in participants aged 12 years and older. The global Phase I/II/III trials enrolled about 44,000 volunteers. (https://bit.ly/3lfaaeF)

(Reporting by Pushkala Aripaka, Vishwadha Chander and Yadarisa Shabong in Bengaluru; Editing by Aurora Ellis and Shounak Dasgupta)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -0.30% 105.97 Delayed Quote.29.99%
PFIZER INC. -2.87% 36.24 Delayed Quote.-1.55%
Latest news "Economy & Forex"
04:49aElectric vehicle firm Faraday Future to go public through $3.4 billion SPAC deal
04:47aWizz Air unfazed by travel slump after quarterly loss
04:42aCENTRAL BANK OF HUNGARY : EBA publishes final draft technical standards to identify investment firms' risk takers and to specify the instruments used for the purposes of variable remuneration
04:32aGameStop slugfest spreads as calls for probe build
04:31aEXCLUSIVE : China likely to avoid setting 2021 GDP target over debt concerns, sources say
04:28aMARKETS DAY AHEAD : How far from GameStop to game over?
04:26aBaFin files Wirecard-related criminal complaint against employee
04:25aLondon stocks drop to near one-month low as lockdown fears weigh
04:24aEasyJet calls for exit-plan from travel curbs to rescue summer
04:20aGlobal stocks soured by Wall Street sell-off and 'vaccine nationalism'
Latest news "Economy & Forex"